GSK plc American Depositary Shares (Each representing two) (NYSE:GSK)
Bands
Volume
200 SMA
50 SMA
20 SMA
Videos
Alerts
Articles
Events
Old Forum Content for GSK
Make a Forum Post Become a member to view recent forum posts. Already a member? Sign in here.
- phgruver: Good morning, y'all. Another pleasant day, here in the southeast. A few scattered showers, floating around, but nothing significant. I'm almost hesitant to mention this, but healthcare $XLV seems to be showing some signs of life. In a long term #VALUE portfolio, this might be a good time to add some to you high dividend payers. I added, small, to my $BMY, which pays a 5.18% dividend that is well supported by earnings. $PFE pays 7.33% (with a bit more headline risk) and $ABBV is at 3.23%. I also own some $GSK which pays 4.02%, but, unlike the others, is a bit extended.
- DavidK: OT- anyone see the NETFLIX film Pain Hustlers? Based off of real company INSYS . Watched it last night . Buddy of mine retired from $GSK and they did many of the same marketing ( wining, dining , entertaining) of Dr’s . Now most of that stuff is illegal .
- phgruver: I'm not seeing much to do, today, but one thing of note: If $PFE holds yesterday's low of $28.27, this may be a good place to add in a LT account. $BMY also looks good right here for an income producing portfolio. Both of these are lagging their peers $ABBV, $GSK, $LLY & $MRK, so I expect them to play catch up.
- woodman: $TERN $VKTX $MDGL $ETNB - Bellus was just bought by $GSK which has results through Phase 2, and now is in Phase 3 with no results due this year.
- Justhanging48: $GSK nice move on volume with the federal dismissal of the Zantac litigation
- Rick_O: @makebackthemill $Anyone $GSK mine opens with simple " GSK "
- StocksnRocks: @makebackthemill $Anyone $GSK
- ag1: $GSK Every patient in this experimental drug trial saw their cancer disappear, researchers say
- halar: @makebackthemill $Anyone After you enter $GSK in TOS , click the "Analyze" tab to give you more info re Glaxo
- makebackthemill: @halar $Anyone $GSK Thanks
- shoredriver: @Shopaholic526 $SRRA ...4/13 YAHOO NEWS $GSK to acquire....found in 35 seconds....
- manoli77: Lot of Pharma stocks looking good today....$ABBV $BMY $GSK
- woodman: @bRobert $mrna $nvax $NVAX $MRNA $PFE - I bought NVAX MRNA and $VIR last week. I wrote about VIR specifically. It (jointly with $GSK) has the only monoclonal antibody believed to be effective against Omicron, at least for now. The other makers of them will catch up in a couple/few months from the sounds of it. On the chart, one will see the obvious breakout area on the weekly chart above the 55-58 area over the course of a long consolidatio/base.
- woodman: $VIR - Last week, I posted about this one. Apparently, it's (jointly with $GSK) monoclonal antibody is the only one that's currently effective against Omicron. Other makers will catch up in time, perhaps a couple/few months. There's a shortage of VIR's/GSK's and medical providers have been stockpiling. In any event, I bought it last week. The chart shows a significant basing/consolidation. Breakout area is ~55-58. It appears to be testing this area in the pre. Happy hunting.
- woodman: $VIR on the weekly, testing resistance level. It has lots of room to move above 55-58 area. It jumped this week on European grant of marketing approval for its joint (with $GSK) monoclonal antibody for early treatment of covid-19. It seems to be the only such treatment holding up against Omicron, so it could get good play in the US. Supposedly there is some stock piling of this in the US.
- kycol: #Covid_Bio Here is my Covid_Bio watchlist: $AZN $BNTX $GSK $JNJ $MRNA $NVAX $PFE $SNY Currently long $JNJ & $PFE. I may take a starter position in $SNY today. News is that the Admin is looking for Covid booster shots for all starting in Sept.
- DAN: @kycol $AZN $BNTX $GSK $JNJ $MRNA $NVAX $PFE $SNY #Covid_Bio Great list, kycol.
- phgruver: @DBones808 $PFE With a 4% dividend, $PFE is a #VALUE stock. You can add it to your LT account and let it grow. You can trade around a core position, but I highly recommend you build a core position in some of the big pharma names. In addition to $PFE, I have $ABBV, $BMY and $GSK.
- Bridget: $NVO $GSK squeeze breakout
- phgruver: @Kharrison67 Good dividend stocks change frequently, because they get overbought. Right now, the utilities $AEP, $DUK, $SO look pretty good, but $D has some question marks that need to be resolved before it's considered "safe". Some of the large pharma names , $ABBV, $BMY, $GSK, $PFE, also look good. $GSK and $ABBV are both in the 5% range on payout. Check the quarterly earnings against the dividend to make sure they can cover it. The BSD's and REIT's that usually dominate the income space aren't particularly safe, right now, because we don't know how badly the COVID displacement will hurt their earnings. High yielders aren't ever "safe" investments, but they have their place in an income portfolio. When all else fails, buy the $SPY or the $QQQ, after it's had a bad day or two.
- phgruver: In looking over my LT holdings, I noticed that $GSK is at a good buy point, if you're looking for income. It's currently paying a 5% dividend, and the price has been trending sideways for several months. Today's news doesn't seem to have had much affect, yet, but this is one of the big boys in Pharma. They are the ones that snap up the biotechs that come up with promising drugs, and bring them to market. Slower movers, but much more reliable growth and income.
- phgruver: @babas $ABT At 1.6% dividend, you are relying on growth for your return. That's fine, but I'm in $BMY, $PFE, $GSK and $ABBV, all of which pay better long term.
-
Sher: ...
Conspicuous by their absence are GlaxoSmithKline ($GSK 0.4%) and Sanofi ($SNY -0.5%).
- Bert953: recently saw a list of covid stocks on cnbc.com here are the tickers: $AMGN $BNTX $CYDY $DVAX $GILD $GSK $HTBX $INO $JNJ $MRNA $NVAX $REGN $ROG $TBIO $TAK $VXRT $VIR
- tnt: $VIR leading ant-viral biotech. Recently announced partnership and investment by $GSK. Excellent long entry here at multiweek support. Descending Bull Flag
- phgruver: @bigbartabs $CVX $XOM My opinion is probably not, but, if oil recovers to the mid $30's, then this price war will just be a blip on the radar. The other stocks I listed $D $GSK $DUK $IBM $PFE are all reasonably safe, although nothing is safe in this environment. It all depends on how long the govt. keeps the economy shut down.
- bigbartabs: @phgruver @champ $CVX $XOM $D $GSK $DUK $IBM $PFE ... big oil dividends... why would we think that dividends are safe with oil in the basement? Can they really keep paying dividends?
- champ: @bigbartabs $CVX $XOM $D $GSK $DUK $IBM $PFE --- For me, I'm only trading. There was a post yesterday by @issues @ 03:22 pm, see his post about dividends because for me, thats only a plus but I'm only Day-trading and Swing-Trading and I'm not doing that for any dividends. I'm not thinking about or even care about dividends for now, in this type of market. .....You need to talk to @issues because he cares, I don't. LOL
- bigbartabs: @champ $CVX $XOM $D $GSK $DUK $IBM $PFE ... not caring about dividends... me either. Dividend cuts are likely to start emerging soon. Probably in volume.
- phgruver: @champ @issues $CVX $XOM I don't like oil, for other reasons, but I tend to agree with your approach. Lots of reliable companies are paying outsized dividends because of the selloff. $D=5.38%, $GSK=5.48%, $DUK=4.87%, $IBM=6.16%, $PFE=4.79%, and the list goes on. I would prefer to pick up these established cash cows, than take on added risk by going for high yield. With these established companies, you are looking at capital gains of 100%, over the next year or two, as well as outsized dividends, and minimal risk. The best of both worlds.
- DAN: Good morning. Stocks are set to open a bit higher today. The number of cases of the covid virus is increasing dramatically, which is expected as more tests are done. I’m not going to recount the news or go into any specifics now or in the fu ...
- Nepenthe: @DAN $MRNA $BLPH $GILD $NVAX $GSK $INO $WORK $ZM $CTXS Another possible one is $JNJ, FWIW. No position. Cheers. "Johnson & Johnson said human testing of its experimental vaccine for the coronavirus would begin by September and that it could be available for emergency use authorization in early 2021. J&J also said it has committed more than $1 billion of investment along with U.S. agency Biomedical Advanced Research and Development Authority, which is part of the Department of Health and Human Services, to co-fund vaccine research. "
- DAN: @Nepenthe $MRNA $BLPH $GILD $NVAX $GSK $INO $WORK $ZM $CTXS $JNJ Will put that on my list. Thanks Nepenthe.
- phgruver: @mradams0621 $LLY not bRobert, but looking at $LLY's chart, I wouldn't buy it RHRN. There are better plays in this space, mostly because $LLY is near it's 52-week low, and still only pays a 2.4% dividend. By contrast, $BMY is near it's 52-week high, and pays over 3%, $GSK pays 4.6% and $ABBV pays almost 6%. If you are investing for the long term, insist on a reasonable, sustainable dividend.(IMHO) $ABT, $PFE and $MRK are similarly richly valued, and $JNJ is uninvestable until they work through their current problems.
- phgruver: @stairm01 $CVS #VALUE $BMY is definitely a #VALUE stock. The dividend is running 3.57%. IMHO, between $45 and $50 is the buy range. Another to look at is $GSK. They are paying 5.16%, at these levels. As a UK based company, they have a different attitude toward dividends than US stocks have. $GSK reports on 5/1. A good report will definitely send them higher.
-
Sher: ...
Shortly following (of course) word hit that the FDA had given Mylan approval for a generic alternative for Advair, one of GSK’s blockbuster drugs for asthma/COPD – At the time, I didn’t know or understand the connection to $INVA &n ... - steve71: @Sher $INVA $GSK Good research. I bet you're gonna be OK with this. I have a mental image of NYC traders who have two things on their desks. One is a Bloomberg terminal. The other is a big red button labelled SELL. Bad news = Push the Button! But that does result in excessive moves, like now, maybe. So, BTO @ 15.62. Good luck.
- Sher: @steve71 $INVA $GSK - Thanks for commenting - I was beginning to feel like a total "dufus"!
-
Sher: @issues $INVA $GSK - Correction on the above (so much for speed reading): That $100 billion figure for Advair is accumulative over the drug’s lifetime. It’s been on the market since 2001. 2018 revenues from Advair were around $750 M.
$ ... - issues: @Sher $INVA $GSK Excellent!Thanks Sher!
- Sher:
- MarkL: @Reif99 $INVA FDA reports approval of Mylan's 'first generic' version of Advair competition for $GSK which would means risk to $INVA royalties … normal sell first ask question later. found on twitter feed
- Reif99: @MarkL $INVA $GSK Thanks! I was lucky, I had a limit order in for 80% of my position that got filled right before the downdraft.
- woodman: @indigo1948 $CLVS I bought twice today. It's moving on the $LLY buyout of $LOXO. Let's review: $BMY -> $CELG $74B $LLY -> $LOXO $8B $GSK -> $TSRO $5B
- woodman: $CLVS $LLY $LOXO $BMY $CELG $GSK $TSRO - acquisitions are moving the space. Interesting graphic. https://pbs.twimg.com/media/DwWVf7JXgAAmkLS.jpg:large
- indigo1948: @woodman $CLVS $LLY $LOXO $BMY $CELG $GSK $TSRO - excellent observation - I own it.
- Forexpro: @Forexpro $PFE $GSK Hi, Friends, Here's the extended hours chart for $GSK. Be lucky!
-
Forexpro: Re: $PFE, $GSK
Hi, Friends,
At least a few investment bankers are smiling this morning (from Dow Jones, via ToS):
" Pfizer Inc. and GlaxoSmithKline PLC plan to combine their consumer-health units, and eventually spin off the joint venture ... - phgruver: Over the weekend, @Dan mentioned drug makers $PFE and $LLY, and rightfully so, as they are both in the winners circle. Worth another look, though, are laggards (value stocks) $BMY and $GSK. Both reported very good 3rd quarters, handily beating expectations. At $50/share, $BMY was a gift. It currently pays a 3% dividend, not outstanding, but nothing to sneeze at either. As for $GSK, this UK based drugmaker has moved up, from $36 to $41, since the beginning of the year. It currently yields 5.18%. Just as importantly, UK based companies have a different attitude toward dividends, and are less likely to cut them. I have LT positions in both, and will add when appropriate....
- CraigReynolds: @phgruver $PFE $LLY $BMY $GSK Been watching a long time, entered $PFE @43. At this time all except $PFE are hard to take another position. Believe health care will be a winner rest of year, but I'm wrong more than correct. What is your thinking about starting either $LLY or $BMY at this time? $GSK seems to have gone up to much for now.
- phgruver: @CraigReynolds $PFE $LLY $BMY $GSK $GSK is at the top of its trading channel, so, unless it breaks above $42, it's wise to wait. $BMY is closer to a buy point, but still in limbo. If it breaks above $54, it's a buy, or, if it pulls back to $52, that could be a buy as well. I haven't been watching $LLY, but it too had a good 3rd qtr, and is now near the top of its trading channel. A @Dan analysis would be that it's a bit extended, but if it breaks out above $115, it could go a up a couple more points. At 2%, the yield isn't going to provide much support.
- phgruver: @Wolf $BMY $BMY has been a solid #VALUE stock since it bottomed at $49.97 on 6/4/18. It only pays $1.60/2.81%, but that's nothing to sneeze at. When it reported 2nd qtr results, a few days ago, it was a monster beat of $1.01 vs consensus of $0.87. Also consider $GSK. It has been doing well since it bottomed at $34.89 back in Feb. It reported a modest beat, $0.79 vs $0.78 expected, on July 25. It currently pays $2.16/5.30%. A better payout, although, arguably, at a slightly higher risk. I own both.
- Wolf: @phgruver $BMY $GSK #VALUE I sold most of it when it spiked after earnings @ 68 and bought back that + more @ 52. Hopefully it blows back through the 200DMA.
- phgruver: @mopick @baron0329 $NKTR $BMY $AEP $AMGN $ABBV $EXEL #VALUE #VALUE No, I'm not interested in biotech for LT holds either. I do have big pharma, though. $BMY is being dragged down by $NKTR, but $MRK, $PFE, $LLY, $ABT even $GSK are worth considering -- at the right price, of course.
-
Gary: ...
4. $GSK – really extended relative to the 200-day MA. Company isn’t growing, so it’s a chart trade.
5. $MCHP – “small position with stop below 200-day MA?” Not a good setup at all b/c of steep selloff. Stop too ... - JonSeale: $GSK breaking out on high volume DAN.
- DAN: @JonSeale $GSK No. Gap and crap. Gapped right up to the 200-day moving average--and the January high--and was sold into. Good omen for the future, though, because it's a sign of demand -- already heavier than average volume. But the stock is still building a base, which could take a while. Not a trading stock. It's a "watching stock." :0)
- JonSeale: @DAN $GSK Cheers.
- phgruver: @baronp0329 @Henry $BMY Add $GSK to your watch list. Both of these drug companies have been hammered, over the past few months. You already know about $BMY, but $GSK also reported good earnings with organic growth. They've also picked up some EU regulatory approvals. As a result, they've reaffirmed their intention to pay the current dividend for the next year. I'm long both. My last add in $BMY was at $56. I'm a little underwater in $GSK, but not enough to fret about.
- phgruver: $BMY has recovered from the news driven selloff on Monday, and is now up over $2, and trading back in the middle of it's 3-month channel. Earnings will be reported on 2/5/18. $GSK is up over 10% from it's December low. Earnings will be 2/7/18. A good earning report may put to rest the rumors of a dividend cut. Until then this remains a cloud over the prospects. Both of these are value plays in a relatively defensive sector.
- cmaxwel1: $MCD $CMS $WM $TD $GSK sold partial positions to fund a house down payment. I like this Trump Market. Feels like Reagan market again.
- dcphinney: @cmaxwel1 $MCD $CMS $WM $TD $GSK Interesting. The smartest guy I know in DC, former chair of commerce, predicted the same thing right after the election.
- cmaxwel1: @dcphinney $MCD $CMS $WM $TD $GSK (people are confident.... lost bid on first house that went over listing price, have bid on new construction today...Things are moving even in the snows of michigan in January. I waited for 2018 to begin selling for lower taxes.
- phgruver: $BMY broke above it's trading channel on below average volume. Having a weak continuation today on average volume. $GSK is also moving. If it can stay above $37.50, it may be worth an add....
- Ajax4Hire: @jan2138 $OXLC I have $OXLC in long term 401k for income; The snap-back today returned a smile to my face; was concerned that the high yield would be swallowed by the decline. Also have for High Yield/Income: $AI, $BP, $ETJ, $F, $GSK, $NRZ and $T. $BP at 7%/year; $F, $GSK and $T at just over 5% a year(when I bought). I am beginning to question $GSK and $T as they seem to feel more investment vs. dividend/income.
- jan2138: @Ajax4Hire $OXLC $AI $BP $ETJ $F $GSK $NRZ $T 5% yields are attractive but not yieldhog territory. Good balance for the riskier tickers.
- mopick: @jan2138 $OXLC $AI $BP $ETJ $F $GSK $NRZ $T, what is your feeling about $STWD? Loan portfolio has a floating rate tied to short-term interest rates so higher rates shouldn't pose a problem. Over 9% yield run by a very savvy CEO.
- meched54: $GSK 5.65% Dividend Barrons's has a nice article on this beaten down drug maker. Popping above 2 months consolidation.
- Bridget: #Notes: FAANG stocks seeing a pop today for the first trading day of the year Chinese stocks seeing a pop $FXI $BABA $BIDU $WB $WUBA $SINA $EDU $ATHM Oil stocks still moving higher. $ETP $BP So is solar $TAN $CBOE / $ICE / $CME - still seeing a pullback $XME $XLB - metals and materials starting off the year with a bang $AKS $CLF $IBB - so is biotech $SMH - still trading sideways $IYT - new high, $FDX $UPS moving up big $XLY hits new high as $XLU continues to sell off $GSK $WRK - breaking out of a squeeze In a squeeze: $HOG $CSCO $AVGO $GLW $AMGN $ADBE $COST $DWDP $DXC $HON $BMY IPOs $LOMA - new high $SEND - new high, but pulled back $MTCH - working $SOI - working
- phgruver: @rck89 $JNJ If you compare $JNJ to the $XLV, you'll find that $JNJ is trading right along with its sector. I'm in $BMY and its doing the same thing. $LLY and $ABT are much the same. A few, like $GSK and $MRK aren't doing quite as well, but overall, the drug stocks are moving along just a bit below the S&P500. Out of favor at the moment, but holding in there.
- phgruver: $BMY Near the top of its trading channel. Needs to get above 64 to break out. $GSK Definitely in the penalty box, but seems to have put in a bottom and is in a pretty tight squeeze. Good support at 35ish. A break above the recent high of 35.77 could lead to a move back above 37. Both of these reported decent earnings, and have gotten positive results from ongoing clinical trials, but have sold off anyway.
- meched54: $GSK 5.8% dividend just started a position.
- phgruver: @Bridget $BMY Also keep an eye on $GSK. It seems to have put in a bottom around 34.50, and has found support around 35. It's coming out of a very tight squeeze. There is resistance between 36 and 36.50, but a move back to 37.50 seems reasonable. Of course, if management backtracks and announces a dividend cut, then all bets are off....
- woodman: @Lou $DVAX - none that I see, though buyout rumors persist ($GSK $MRK).
-
1winkie: ...
$GSK - was raised to Buy from Neutral at UBS. Its American depositary shares closed at $35.04 on Friday and were indicated up 2.3% at $35.85 on Monday, in a 52-week range of $34.72 to $44.54 and with a consensus target price of $43.33.
$SQ - was do ... - DAN: @1winkie $ACM $CIEN $AQUA $FNKO $GSK $SQ $ALNA $ALTR $BWLD $DLPH Great post, 1winkie. Thanks for this great information. You can write my morning note anytime you want. ;-) Dan
- phgruver: $GSK, delayed reaction to the FDA approval last week of ViiV Healthcare's two-drug HIV Regimen. $GSK is the majority owner of ViiV. Today, USB upgraded $GSK to "Buy" from "Neutral." This is a value and income play. $GSK pays 5.9%, but that payout is being questioned by some funds. The EPS is $1.27, and the dividend $2.07, so that's not sustainable without significant growth.
- phgruver: Good news for $GSK (they need it!). The FDA has approved a 2 drug therapy for HIV called Juluca. This therapy is produced by ViiV Healthcare, which is majority owned by $GSK. $PFE is a minority stake holder as well, so they may see a pop as well.
- phgruver: $GSK goes Ex-div today for about 50 cents (it's computed in GBP and converted.) It will be interesting to see what happens. $GSK is down from $44.53 on 5/31/17 to yesterday's close at $35.98. That's a decline of $8.55, or about 20%. Too soon to call a bottom, but it's worth watching. (Institutions are concerned that $GSK may have to cut their dividend.)
- phgruver: $GSK, $BMY $MRK all took a dive after earnings. All seem to be stabilizing at lower levels. These are slow growers that produce steady income. $MRK pays 3.41%, $GSK pays 5.56% and $BMY pays 2.53%. If they continue to hold in this area, it could be a good place to add. Remember that some institutional investors are questioning $GSK's ability to continue to pay $.50+/qtr. The dividends of the other two seem safe, for now.
- phgruver: $GSK reports before the open today. Expectations are for $0.83/share earnings on earnings of GBP7.84 billion. We'll know soon....
- phgruver: $GSK: the conference call is on going, but, at first glance, investors aren't impressed. The recent low, in Aug, was 38.60. It's getting close to that. Overall, the call seems to indicate that $GSK met company expectations (not necessarily Wall Street's) and reaffirmed guidance for the year. $GSK is not going out of business, and remains a market leader in this space. I think this is going to be a buying opportunity. I'll wait for the dust to settle and then consider adding. Edit: An interesting final note. When pressed about the possibility of a dividend cut, the CEO referred to any discussion of that possibility as "premature." In other words, she evaded the question.
-
rachel: ...
@phgruver gave some insight into the earnings of $GSk
@grcjr gave their thoughts on how $AMD’s earnings could be affecting $INTC today
@bsafriet gave some insight into how $SPX might technically have shown overbought conditions before today& ... - utex72: @phgruver $GSK Are you concerned about, what appears to be, institutional selling; 8.7M shares so far today?
- phgruver: @utex72 $GSK Something to watch, but no, it just brought the price down to the 20DMA, which is the lower end of the short term trading channel, and then traded up for most of the day, closing higher than it opened. This is just "healthy" back and forth trading. They report earnings next Wed, 10/25, so I would be cautious if you are thinking about starting a position right here. A sell off on earnings would be a better opportunity. Expectations are for .83/share, up from .70/share this quarter. Remember, I was adding to an existing position.
- Wolf: $GSK Tight squeeze, testing the upper range. Break of the 200 DMA .07 higher will probably start an eaarnings run (10/25). Long 10/27 41 calls.
- phgruver: Added to two positions to boost income. $GSK is in an ascending channel. Unfortunately, it is near the top of the channel, but, the channel is fairly narrow and at a gentle slope, so the risk of it dropping from $41 to $40.75 is acceptable. I really don't see it pulling back below 40.50. Current yield is 4.94%. The other is $NRZ, which is yielding 11.66%. More risk here, but it has been trading sideways long enough for the 50DMA to catch up. As long as it stays above $17, I'm good.
- DrScience: $AET $UNH $CI $HUM $ANTM, et al... indigestion getting worse. $ANTM through the 200 DMA, $HUM and $AET through the 50, $UNH testing the 50. Better take a position in Tums, i.e. $GSK!
- phgruver: $GSK An engulfing day on heavy volume closing near the HOD. This is probably a reversal. Yield is 4.88%.
- bigtex123: @phgruver $GSK Hi, we traded messages a few months ago. Any thoughts on current slide? I nibbled on way down, so my position size has gotten bigger. I'm at break even but plan to keep for long term and dividend. Thx for any thoughts. Bo
- phgruver: @bigtex123 $GSK 2nd Qtr earning was a beat, but they lowered guidance, and canceled some of their research projects. The next few trading sessions will be "price discovery" sessions as the stock searches for support. Frankly, I would want it to hold here at $40, but the next support is around $38. This is a pretty steep decline! If I was at "break even", I'd be inclined to sell here, hang onto the money and plan to buy back a bit lower, once the dust settles. The next ex-dividend date will be around Aug 10, so you've got a couple of weeks. The yield is getting near 5% which is going to attract attention....
- phgruver: @bigtex123 $GSK I just checked my position. It's in a ROTH, and my cost basis is right where the stock is trading this morning, but it's not that big a position. I'll probably just ride it out. I really don't think $GSK is in danger of going under. It may take a year or two to get their mojo back, though....
- tejas7: $GSK nice dividend, nice chart
- mopick: @bigtex123 $GSK out of the country, still holding but small position. Have similar concerns as you.
- phgruver: @bigtex123 $GSK Sorry about not seeing this. I haven't been watching the market too closely this week, I have other things to do.... I hold $GSK in a ROTH account, so I'm not looking to trade it. Instead, I'm looking for good entries for building ...
- bigtex123: @phgruver $GSK hi. are you still long GSK? Im considering selling, worried about the sector and I have other names that have better dividend coverage and less debt. Curious what your current thoughts were, if any. Thank you.
- bigtex123: $AMGN anyone have any insights on AMGN? I started new position last week at 162, planning to keep it for year or two for the yield and steady/low growth. However, Barron's on Saturday mentioned AMGN as a stock to avoid long term b/c of their inflated drug prices. $PFE and $GSK were also mentioned negatively but they offer more attractive yields that compensate for some of the additional risk. AMGN yield of 2.6% does not really compensate me. I guess I underestimated the AMGN risk. Thank you for any insights.
- bigtex123: @pilotski $ABMD I own it. Barron's had a negative article over the weekend about price gouging. $PFE, $AMGN, $GSK also mentioned negatively. Hoping it will blow over.
- bigtex123: @bigtex123 $ABMD $PFE $AMGN $GSK correction. $ABMD was not mentioned in the article. $ABBV was, I get them confused. Sorry.
- mopick: @Wolf $T good question. I've been toying with the idea of adding to my IRA. Guess it depends on what your time horizon is? Not much growth, just the dividend. Probably could find something in its place that has more growth with an equal or higher dividend yield. I've been looking at $GSK which has a better yield & better prospects. That said, if it dips below todays low, or below $40, 200 dma, I'd likely jettison it.
| Stock Price | $43.35 |
| Change | -0.78% |
| Volume | 13,115,700 |
GlaxoSmithKline PLC incorporated in United Kingdom. The Company creates, discoveres, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Request Video of GSKAlready a member? Sign in here.
Past Month
Leading Peers
-
$45.43 22.52%
-
$489.88 17.75%
-
$20.64 17.13%
Past Month
Lagging Peers
-
$28.54 -33.88%
-
$15.78 -23.60%
-
$8.66 -15.88%
Dan Fitzpatrick
Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:
- Nightly video Strategy Sessions with a game plan for tomorrow
- Got a stock you want Dan to look at? Just ask.
- Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
- Access to over 90,400 stock analysis videos
- Access an ever expanding library (90,400) of educational videos that will save you time and make you money
Join a team of friends and traders that have one thing in common; a burning desire to succeed.
Become a Member Today!
Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...
Satisfaction Guaranteed!
Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!